Screening of


Journal

Journal of medical genetics
ISSN: 1468-6244
Titre abrégé: J Med Genet
Pays: England
ID NLM: 2985087R

Informations de publication

Date de publication:
02 2019
Historique:
received: 12 07 2018
revised: 16 10 2018
accepted: 28 10 2018
pubmed: 26 11 2018
medline: 19 5 2020
entrez: 26 11 2018
Statut: ppublish

Résumé

Genetic analysis of We analysed A novel transcript was detected in Screening of

Sections du résumé

BACKGROUND
Genetic analysis of
METHODS
We analysed
RESULTS
A novel transcript was detected in
CONCLUSION
Screening of

Identifiants

pubmed: 30472649
pii: jmedgenet-2018-105606
doi: 10.1136/jmedgenet-2018-105606
doi:

Substances chimiques

BRCA1 Protein 0
BRCA1 protein, human 0
BRCA2 Protein 0
BRCA2 protein, human 0
RNA, Messenger 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

63-74

Informations de copyright

© Author(s) (or their employer(s)) 2019. No commercial re-use. See rights and permissions. Published by BMJ.

Déclaration de conflit d'intérêts

Competing interests: None declared.

Auteurs

Gemma Montalban (G)

Oncogenetics Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.

Sandra Bonache (S)

Oncogenetics Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.

Alejandro Moles-Fernández (A)

Oncogenetics Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.

Alexandra Gisbert-Beamud (A)

Oncogenetics Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.

Anna Tenés (A)

Area of Clinical and Molecular Genetics, University Hospital of Vall d'Hebron, Barcelona, Spain.

Vanessa Bach (V)

Oncogenetics Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.

Estela Carrasco (E)

High Risk and Cancer Prevention Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.

Adrià López-Fernández (A)

High Risk and Cancer Prevention Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.

Neda Stjepanovic (N)

High Risk and Cancer Prevention Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.
Medical Oncology Department, University Hospital of Vall d'Hebron, Barcelona, Spain.

Judith Balmaña (J)

High Risk and Cancer Prevention Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.
Medical Oncology Department, University Hospital of Vall d'Hebron, Barcelona, Spain.

Orland Diez (O)

Oncogenetics Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.
Area of Clinical and Molecular Genetics, University Hospital of Vall d'Hebron, Barcelona, Spain.

Sara Gutiérrez-Enríquez (S)

Oncogenetics Group, Vall d'Hebron Institut d'Oncologia, Barcelona, Spain.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH